학술논문
S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
Document Type
article
Author
Source
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Subject
Language
English
ISSN
2053-8790